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Abstract
Introduction: IgG anti-apolipoprotein A-1 (IgG anti-apoA-1) antibodies are present in patients with systemic lupus
erythematosus (SLE) and may link inflammatory disease activity and the increased risk of developing atherosclerosis
and cardiovascular disease (CVD) in these patients. We carried out a rigorous analysis of the associations between
IgG anti-apoA-1 levels and disease activity, drug therapy, serology, damage, mortality and CVD events in a large
British SLE cohort.
Methods: Serum IgG anti-apoA-1 levels were measured in 100 healthy controls to define a cut-off for positivity. In
499 patients with SLE we obtained the earliest stored serum sample from their disease course and measured IgG
anti-apoA-1 level. We then examined associations between IgG anti-apoA-1 positivity in early disease and the
development of damage, CVD or death over a mean follow-up period of 12.1 years in these patients. In a separate
study, we measured IgG anti-apoA-1 levels in 397 samples taken longitudinally from 49 patients with SLE over a
mean period of 89 months of fluctuating disease activity and carried out multi-variable analysis to examine the
demographic, serological, disease activity and treatment factors associated with IgG anti-apoA-1 level over time.
Results: In the longitudinal study, IgG anti-apoA-1 levels were significantly higher in patients with persistently
active disease, those on high dose corticosteroid and those not taking hydroxychloroquine. Of the 499 subjects
who had early disease IgG anti-apoA-1 levels measured, 135 (27%) were positive. However, we found no convincing
associations between early IgG anti-apoA-1 positivity and development of damage, mortality or CVD.
Conclusions: IgG anti-apoA-1 developed early in a quarter of our patients with SLE, but this had no major impact on
subsequent clinical outcomes. However, levels of IgG anti-apoA-1 vary over time and are associated with disease
activity, treatment with high dose corticosteroid and not taking hydroxychloroquine.
Introduction
Antibodies to apolipoprotein A-1 (anti-apoA-1) have
been reported in the serum of patients with systemic
lupus erythematosus (SLE) [1-4]. Several groups found
independently that levels were elevated in patients with
active SLE compared with inactive SLE [1-4], although
none carried out multivariable analysis to exclude the
effect of confounding factors. Apolipoprotein A-1 is the
main constituent of high-density lipoprotein, which plays a
major role in preventing atherosclerosis [5,6]. It has been
suggested that anti-apoA-1 could interfere with this pro-
tective effect and thus promote atherosclerosis [2,4]. IgG
anti-apoA-1 have also been associated with markers of in-
creased plaque vulnerability such as intra-plaque macro-
phage, neutrophil and matrix metalloproteinase content
[7] and are associated with increased levels of the surrogate
plaque vulnerability markers interleukin-6, tumour necro-
sis factor alpha and matrix metalloproteinase-9 in patients
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levels are found in patients with acute coronary syndromes
[9], are a risk factor for major cardiovascular events in the
12 months after myocardial infarction [10] and are associ-
ated with significantly increased risk of major cardiovascu-
lar events in patients with rheumatoid arthritis (RA) [11].
Anti-apoA-1 antibodies have thus attracted particular
interest as a possible mediator between inflammation and
the recognised increased risk of developing cardiovascular
disease (CVD) in patients with SLE.
In a large multinational study of 9,547 patients with SLE
there were 1,255 deaths, of which 313 were due to CVD
[12]. Patients with SLE have fivefold to 10-fold greater risk
of developing CVD than age-matched controls [13], rising
to 50-fold in women between the ages of 35 and 44 [14].
Subclinical vascular disease is more common in patients
with SLE than in age-matched and sex-matched controls
[15,16]. Patients with SLE who suffer CVD events do so at
ar e l a t i v e l yy o u n ga g e– a mean of 49 years for women
[13]. Standard methods based on the Framingham equa-
tions underestimate CVD risk in patients with SLE
[17,18]. Alternative stratification tools to identify athero-
sclerosis – for example, vascular ultrasound – may be use-
ful [19,20]. If IgG anti-apoA-1 have a true predictive value
for CVD this could also be helpful. Previously, we did not
find high IgG anti-apoA-1 levels in 24 patients with SLE
who suffered CVD events [2]. Radwan and colleagues
found no relationship between IgG anti-apoA-1 and ca-
rotid intima-media thickness in 80 Egyptian patients with
SLE but, unlike most other SLE groups studied, none of
their patients had carotid plaques [4].
Previous studies of IgG anti-apoA-1in patients with
SLE were limited by having small numbers of patients,
lack of multivariable analysis and short-term follow-up
after the samples were taken. Here, we address these is-
sues to answer the following questions: which demo-
graphic, serological, clinical and treatment factors are
significantly associated with changing IgG anti-apoA-1
levels over time in patients with SLE? What is the preva-
lence of positivity for IgG anti-apoA-1 early in the dis-
ease course of SLE? Does positivity for IgG anti-apoA-1
early in the disease course predict subsequent damage,
cardiovascular disease and/or mortality?
Methods
Ethical approval for all parts of the study was granted by
the joint University College London/University College
London Hospitals Research Ethics Committee (Reference
06/Q0505/79) and subjects gave informed consent for use
of their stored serum samples.
Healthy control subjects
We tested samples from 100 healthy control subjects ori-
ginally obtained as part of the Health Survey for England
2006 [21]. The samples were provided to us by the Health
and Social Care Information Centre together with
anonymised data on age, and the gender and ethnicity
of the subjects and absence of long-term illness or pre-
vious CVD were confirmed. Their median age was
43 years (range 20 to 69), 49% were female and the eth-
nic distribution was 83% Caucasian, 8% Afro-Caribbean
and 9% South Asian.
Patients with systemic lupus erythematosus
The University College London Hospitals SLE clinic has
been running since 1979 and we have followed over 600
patients with SLE since then, all fulfilling the revised
American College of Rheumatology classification criteria
[22]. From this population of patients we selected two
different groups who were studied to answer different
questions.
Early disease group
For 499 patients we were able to obtain serum samples
taken within 1 year of diagnosis and stored at −80°C.
The earliest of these samples was obtained in 1978 and
the most recent in 2011. We tested all of these samples
for IgG anti-apoA-1 antibodies – using the enzyme-
linked immunosorbent assay (ELISA) described below –
to find out what proportion of patients with SLE have
IgG anti-apoA-1 early in the disease course. These 499
patients with SLE had been under continuous follow-up
for between 1 and 34 years (mean 12.1 years). We inves-
tigated whether positivity for IgG anti-apoA-1 within the
first year of the disease was associated with the following
outcomes: death from any cause; death before the age of
60; CVD – defined as either myocardial infarction with
typical enzyme and/or ECG changes, ischaemic stroke
confirmed by imaging or non-infarct coronary disease
confirmed by angiography; and damage as measured by
the Systemic Lupus International Collaborative Clinics
Damage Index (SLICC-DI) [23].
Data on death and CVD were available for all 499 pa-
tients from review of their clinical records. Data on
SLICC-DI scores were only available for 236 patients.
These patients had been studied between 2006 and 2008
in a project designed specifically to collect comprehen-
sive data on damage scores from patients who had been
followed in the clinic for at least 10 years by then (that
is, had been diagnosed between 1979 and 1996) [24].
Only 236 such patients were available and thus only
SLICC-DI data from those patients are included in the
current report.
For the early disease samples we did not have data on
other autoantibodies, or on the disease activity or dam-
age scores at the time of the sample.
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Longitudinal serum samples (n=397) were selected retro-
spectively from a group of 49 patients with SLE with a
mean of eight samples per patient (standard deviation
(SD) 2.16; minimum 3; maximum 14) that had been ob-
tained during a mean period of 89 months (SD 46; mini-
mum 14; maximum 180) in the course of their disease.
The patients were selected on the basis that they had vary-
ing levels of disease activity over time, including examples
of flares in all of the main organs and systems of the body.
By coincidence, 47 patients in this group were also mem-
bers of the early disease group, but the longitudinal serum
samples used in this part of the project were different
from the early disease samples used in the other part of
the project.
For all samples where data were available (94%), we ob-
tained anti-dsDNA and complement C3 levels and disease
a c t i v i t yf r o mt h ed a t eo ft h es a m p l ea n df r o mt h ep r e v i o u s
three assessments. Anti-dsDNA and C3 were measured in
the routine clinical laboratory at University College London
Hospitals using the ELISA (Shield Diagnostics, Dundee,
UK) and laser nephelometry respectively. Based on the nor-
mal limits for our laboratory, anti-dsDNA level >50 IU/ml
was defined as high and C3 level <0.9 g/l as low.
Disease activity was measured using the classic British
Isles Lupus Assessment Group (BILAG) index [25]. The
more recent BILAG 2004 index was not used because
many of the samples had been taken before 2004. Dis-
ease activity over the most recent four assessments was
characterised as persistently low activity (all systems
BILAG C, D or E) or persistently moderate–high activity
(A or ≥1 B in any BILAG system on at least 2/4 occa-
sions). Over 90% of all samples fell into one of those two
categories and the rest were excluded from this part of
the analysis. Global BILAG score was calculated using
the formula A =12, B=5, C=1, D =E =0 as described
previously [26].
Data on ethnicity, gender, drug therapy and the anti-
Sm, anti-RNP, anti-Ro and anti-La (all tested by ELISA)
status of the patients were obtained from the clinical re-
cords of the patients. We did not have data on SLICC-
DI score at the time of each sample.
Direct ELISA to detect IgG anti-ApoA-1 antibodies
IgG anti-ApoA-1 antibodies were detected by a modifi-
cation of the direct ELISA protocol described previously
[2,27]. All steps were carried out at 37°C except where
specified. A Nunc-Maxisorb 96-well ELISA (Fisher Scientific,
Loughborough, UK) plate was divided in half. One side (the
test side) was coated with 10 μg/ml apolipoprotein A-1
(A0722; Sigma St Louis, Missouri, USA) in 70% ethanol. The
other side (the control side) was coated with 70% ethanol.
After incubation for 90 minutes, the plates were washed
and blocked with 1% bovine serum albumin diluted in
phosphate-buffered saline for 1 hour. Serum samples at 1:50
dilution in 1% bovine serum albumin–phosphate-buffered
saline were tested in duplicate such that each sample was
added to two test wells and two control wells. On each
plate, a seven-point dilution of the positive control (a
pool of six serum samples from patients known to have
high serum IgG anti-apoA-1) was performed starting at
1:25 dilution. Following incubation for 1 hour, goat anti-
human IgG–alkaline phosphatase conjugate (A3150;
Sigma) diluted 1:1,000 in 1% bovine serum albumin–phos-
phate-buffered saline was added at room temperature for
1 hour followed by alkaline phosphatase substrate. Ab-
sorbance at 405 nm was recorded after 60 minutes. The
net optical density (OD) reading for each sample was cal-
culated by subtracting the OD in the control well from
that in the matching test well to exclude nonspecific back-
ground binding. The mean net OD from the duplicate
samples was converted to absorbance units (AU) by com-
parison with the standard curve of OD for the serial dilu-
tions of the positive control sample on each plate. A value
of 100 AU was defined as the OD given by a 1:50 dilution
of the positive control sample. This assay was reproducible
with intraplate and interplate coefficients of variation <10%.
Statistical analysis
In the longitudinal group, assessment of anti-ApoA-1
levels showed a highly positive skewed distribution, which
could not be transformed to a normally distributed scale.
The outcomes were thus assumed to follow a negative bi-
nomial distribution. Owing to the longitudinal nature of
this group, multiple samples for each patient were consid-
ered. To allow for the non-independence of the data,
multilevel statistical methods were used for analysis. Two-
level models were used with individual measurements
clustered within patients. The analyses, performed using
multilevel negative binomial regression, were performed
in two stages. Firstly the separate effect of each factor
upon the outcome was examined in a series of univariable
analyses. Subsequently the joint effect of factors was ex-
amined in a multivariable analysis. A backward selection
procedure was employed to retain only the statistically sig-
nificant variables. Variance inflation factors were used to
assess collinearity between variables, and as a result some
variables that were collinear with other variables were ex-
cluded from the multivariable stage of the analysis.
In the early disease group, associations between anti-
ApoA-1 levels and clinical outcomes were analysed using
the statistical analysis software Prism. Univariable analysis
was performed using the Mann–Whitney U test, as the
sample did not follow a normal distribution. Statistical sig-
nificance was considered when P <0.05. Survival curves
for cardiovascular disease events and mortality were pro-
duced using the Kaplan–Meier method. For the analysis
of mortality, patients who were not known to have died
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of the study period or at the time of loss to follow-up if
that applied (for example, patients who moved away from
London). For the analysis of CVD events, patients who
had no such events were censored at the time of death,
loss to follow-up or the end of the study period. The sur-
vival curves were compared using the log-rank test.
Results
Longitudinal group: elevated IgG anti-apoA-1 level was
associated with high disease activity, high-dose steroids
and not being treated with hydroxychloroquine
The mean age of the 49 patients in the longitudinal group
was 36 years (SD 13.0) and 81% were female. Twenty-
three patients were Caucasian, 18 were Afro-Caribbean
and eight were other ethnicities. Twenty-one patients
were anti-Ro-positive, six were anti-La-positive, 15 were
anti-RNP-positive and 11 were anti-Sm-positive. During
the follow-up period, 29 patients had at least one elevated
anti-dsDNA level, 32 had at least one low C3 level and 46
suffered at least one flare (BILAG A or B in at least one
system). Flares in all eight systems of the classic BILAG
index were represented in the cohort.
Figure 1 shows that the IgG anti-apoA-1 level was
higher in the 397 samples from patients with SLE (median
48.5, interquartile range (IQR) 16.0 to 87.5) than in the
100 healthy controls (median 8.0, IQR 5.9 to 10.7) (P=
0.0001). A positivity cutoff value was defined as the 97.5th
percentile of 100 healthy controls (46.7 AU). Fifty per cent
of the samples from patients with SLE were found to be
IgG anti-ApoA-1-positive.
Table 1 presents the results of univariable analysis to as-
sess association of 24 clinical, demographic and serological
variables with serum IgG anti-apoA-1 level.
IgG anti-apoA-1 levels were significantly lower in pa-
tients with positive anti-La and anti-Sm but there was
no relationship with C3 or anti-dsDNA.
Patients with persistent moderate/high disease activity
had 30% higher IgG anti-apoA-1 levels than those with
persistently low activity. Those with haematological
BILAG scores of A or B on the day of the sample had
higher IgG anti-apoA-1 levels than those with scores of C,
Do rE( P <0.001). A similar trend was observed for pa-
tients with renal or cardiorespiratory A or B scores al-
though statistical significance was not reached (P=0. 06
for both).
Patients treated with hydroxychloroquine had IgG anti-
apoA-1 levels 30% lower than those who were not taking
hydroxychloroquine, whereas those on higher dose pred-
nisolone (>7.5 mg/day) had levels 39% higher than those
taking lower doses.
Table 2 presents the results of multivariable analysis. No
collinearity was observed between variables. Only negativ-
ity for anti-La and anti-Sm, haematological disease activity
and taking higher dose prednisolone remained as inde-
pendently associated variables.
As shown in Figure 2, IgG anti-apoA-1 levels varied
over time and paralleled disease activity (measured by
global BILAG score) closely in many (Figure 2A,B,C,D,E,
F), but not all patients (Figure 2G,H).
IgG anti-apoA-1 positivity was seen in 27% of early disease
samples and was not associated with mortality or CVD
The mean age of the 499 subjects at the time when the
early disease sample was taken was 30 years (SD 12.27,
range 1 to 77) and 91.5% were female. Ethnic distribution
was Caucasian 61%, African/Caribbean 20.5%, South
Asian 11.4%, East Asian 4.6%, and other 2.5%.
Median IgG anti-apoA-1 levels were significantly higher
in patients with SLE (median 21.4 AU, IQR 11.2 to 52.9)
than in healthy controls (median 8.0 AU, IQR 5.9 to 10.7)
(P <0.05) and 27% of patients tested positive in the first
sample obtained after diagnosis of SLE. There was no
correlation between the order of acquisition of samples
and IgG anti-apoA-1 level (Spearman correlation coeffi-
cient −0.115), suggesting that storage time does not
affect IgG anti-apoA-1 level.
As seen in the longitudinal group, there were no sig-
nificant associations between IgG anti-apoA-1 level and
age, gender or ethnicity.
During follow-up, 40 patients (8.0%) suffered a CVD
event; that is, coronary heart disease confirmed by en-
zyme or electrocardiography changes of myocardial in-
farction or by angiography for nonmyocardial infarction
CAD or ischaemic stroke confirmed by imaging. The
prevalence of CVD events did not differ between anti-
apoA-1-positive and anti-apoA-1-negative patients (6.7%
vs. 8.5%, P >0.05). A Kaplan–Meier survival curve showing
Figure 1 Comparison of IgG anti-apoA-1 levels in serum
samples from patients with SLE and healthy controls. anti-apoA-
1, antibodies to apolipoprotein A-1; AU, absorbance units; HC,
healthy controls; IgG, immunoglobulin G; SLE, systemic
lupus erythematosus.
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Variable Category Ratio (95% CI) P value
Gender
a Female (n=336) 1
Male (n= 61) 1.20 (0.85, 1.69) 0.30
Disease duration Ratio given per 5-year increase 1.00 (0.90, 1.11) 0.99
Age (at diagnosis) Ratio given per 10-year increase 1.02 (0.88, 1.18) 0.81
Ethnicity
a Caucasian (n= 182) 1
Afro-Caribbean (n=146) 1.19 (0.90, 1.57)
Other (n=69) 1.07 (0.75, 1.53) 0.46
Any ENA
b No (n= 165) 1
Yes (n=232) 0.82 (0.63, 1.06) 0.13
Anti-Ro
b No (n= 226) 1
Yes (n-171) 0.90 (0.69, 1.17) 0.41
Anti-La
b No (n= 345) 1
Yes (n=52) 0.54 (0.36, 0.80) 0.002
Anti-Sm
b No (n= 298) 1
Yes (n=99) 0.64 (0.47, 0.87) 0.004
Anti-RNP
b No (n= 288) 1
Yes (n=109) 1.11 (0.84, 1.47) 0.46
Anti-dsDNA level <50 IU/ml (n=177) 1
≥50 IU/ml (n= 170) 1.13 (0.90, 1.43) 0.29
C3 level <0.9 g/l (n=139) 1
≥0.9 g/l (n= 208) 0.82 (0.66, 1.03) 0.09
Disease activity in general system
c A, B (n= 31) 1
C, D, E (n=344) 0.84 (0.60, 1.18) 0.32
Disease activity in mucocutaneous system
c A, B (n= 41) 1
C, D, E (n=334) 0.89 (0.65, 1.22) 0.48
Disease activity in neuropsychiatric system
c A, B (n= 18) 1
C, D, E (n=357) 0.93 (0.57, 1.52) 0.77
Disease activity in musculoskeletal system
c A, B (n= 47) 1
C, D, E (n=328) 0.80 (0.60, 1.08) 0.14
Disease activity in cardiorespiratory system
c A, B (n= 13) 1
C, D, E (n=362) 0.66 (0.42, 1.02) 0.06
Disease activity in vascular system
c A, B (n= 12) 1
C, D, E (n=363) 0.80 (0.47, 1.34) 0.40
Disease activity in renal system
c A, B (n= 41) 1
C, D, E (n=329) 0.75 (0.55, 1.01) 0.06
Disease activity in haematological system
c A, B (n= 95) 1
C, D, E (n=280) 0.63 (0.50, 0.79) <0.001
Overall disease activity over last four assessments Persistently low (n= 166) 1
Persistently moderate/high (n=209) 1.30 (1.06, 1.59) 0.01
Hydroxychloroquine
d No (n= 223) 1
Yes (n=174) 0.70 (0.55, 0.88) 0.003
Immunosuppression
d No (n= 200) 1
Yes (n=197) 0.90 (0.73, 1.12) 0.35
Oral prednisolone
d ≤7.5 mg/day (n=101) 1
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anti-apoA-1-negative groups free of CVD at all time points
up to 34 years of follow-up showed no significant differ-
ence between groups (Figure 3; P=0 . 8 9b yl o g - r a n kt e s t ) .
Similarly, positivity for IgG anti-apoA-1 did not pre-
dict onset of damage during follow-up. Table 3 presents
damage scores at 5, 10, 15 and 20 years after stratifica-
tion into quartiles based on the early disease sample IgG
anti-apoA-1 level with no significant differences in dam-
age score between the quartiles at any time point.
During follow-up, 63.0% and 24.0% of patients were at
some time positive for anti-dsDNA and anti-cardiolipin anti-
bodies respectively. One-quarter of the patients were found
to be rheumatoid factor-positive and over one-half were
positive for antibodies to extractable nuclear antigens (14.9%
anti-Sm, 27.8% anti-RNP, 37.5% anti-Ro and 13.9% anti-La).
Patients who developed anti-dsDNA positivity had
higher IgG anti-apoA-1 in their early disease samples than
those who did not (median 22.5 AU vs. 17.1 AU, P=
0.0012) and a similar relationship was found for those
who developed anti-cardiolipin antibodies (IgG anti-
apoA-1 25.5 AU vs. 21.0 AU, P= 0.025). There were no re-
lationships with other autoantibodies.
Regarding mortality, 13% of patients died (n=66), 48
of them before the age of 60. A Kaplan–Meier survival
curve showing the percentage survival of subjects in the
anti-apoA-1-positive and anti-apoA-1-negative groups at
all time points up to 34 years of follow-up showed no
significant difference between groups (Figure 4; P =0.22
by log-rank test).
There was no indication that deaths in patients youn-
ger than 60 or in patients with raised IgG anti-apoA-1
were due disproportionately to CVD. In the over 60s,
the causes of death were 17% CVD, 44% cancer, 17% in-
fection, 6% renal and 17% other. In the under 60s, the
causes were 13% CVD, 17% cancer, 31% infection, 8%
renal and 31% other. Of the six patients who died from
CVD under the age of 60, only one had positive IgG
anti-apoA-1 at the time of diagnosis.
Discussion
Previous studies confirmed the presence of IgG anti-
apoA-1 antibodies in patients with SLE, indicated an as-
sociation with higher disease activity and suggested a
possible link with the development of CVD [1-4]. In this
paper we have confirmed the association with disease ac-
tivity by carrying out multivariable analysis of factors af-
fecting IgG anti-apoA-1 levels in longitudinal samples
from a group of 49 patients whose disease activity varied
over time. We investigated the prevalence of elevated
IgG anti-apoA-1 in early disease and its predictive value
for CVD and mortality by studying 499 patients followed
for a mean of 12.1 years after the date of the sample.
We showed that 27% of 499 patients were positive for
IgG anti-apoA-1 very early in the disease course. Arbuckle
and colleagues showed that many autoantibodies are
present in patients with SLE even in stored samples taken
before diagnosis of SLE [28]. However, anti-apoA-1 levels
in early disease samples have not been studied before.
We found no association between IgG anti-apoA-1 posi-
tivity early in disease and increased risk of dying as survival
curve analysis showed no difference between the anti-
apoA-1-positive and anti-apoA-1-negative groups. Devel-
opment of damage (due to disease activity or therapy) is a
Table 1 Univariable analysis of factors associated with serum IgG anti-apoA-1 levels in the longitudinal group
(Continued)
>7.5 mg/day (n=296) 1.39 (1.13, 1.71) 0.002
Bold data indicate values of P <0.05. anti-apoA-1, antibodies to apolipoprotein A-1; BILAG, British Isles Lupus Assessment Group; CI, confidence interval; IgG, immunoglobulin
G. ENA; antibodies to extractable nuclear antigens.
aFor gender, n values refer to the numbers of samples taken from female and male subjects, rather than numbers of
females and males in the cohort of patients. A similar stipulation applies to ethnicity, where n values refer to the number of samples taken from patients of each ethnic
group.
bFor ENA, anti-Ro, anti-La and anti-Sm, we did not have results from the date of every sample but it is assumed that positivity and negativity for these antigens
generally remain stable.
c ‘Disease activity in general system’ refers to the BILAG score (A, B, C, D or E) in the General Category of the BILAG index on the day when each
sample was taken. The same principle applies to all of the other organ systems listed in the table, which are the eight different categories recorded in the BILAG.
dRefers
to drugs being taken on the date of the sample.
Table 2 Multivariable analysis of factors associated with IgG anti-apoA-1 level in the longitudinal cohort
Variable Category Ratio (95% CI) P value
Anti-La No 1
Yes 0.58 (0.39, 0.86) 0.006
Anti-Sm No 1
Yes 0.58 (0.43, 0.80) 0.001
Activity in the haematological system A, B 1
C, D, E 0.66 (0.53, 0.83) <0.001
Steroids ≤7.5 mg/day 1
>7.5 mg/day 1.34 (1.08, 1.66) 0.008
anti-apoA-1, antibodies to apolipoprotein A-1; CI, confidence interval; IgG, immunoglobulin G.
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no association between IgG anti-apoA-1 level and SLICC-
DI score over a 10-year follow-up period in over 200 pa-
tients (Table 3).
We found no association between IgG anti-apoA-1
positivity early in disease and development of CVD later.
The numbers of patients with CVD were relatively small
(40/499). We have thus found no convincing link be-
tween IgG anti-apoA-1 and CVD in patients with SLE in
this study. This finding agrees with those of Radwan and
colleagues [4] in Egyptian patients with SLE but con-
trasts with those of Vuilleumier and colleagues, who
found that, in 133 Swiss patients with RA followed for a
median of 9 years [11], baseline IgG anti-apoA-1 positivity
was strongly associated with risk of developing a major
cardiovascular event (hazard ratio 4.7, 95% confidence
interval 1.9 to 11.2), even after adjusting for standard
CVD risk factors in multivariable analysis. However, this
RA cohort was older (mean age 65 years), contained more
males (30%) and had higher rate of CVD events compared
Figure 2 Longitudinal variation in IgG anti-apoA-1 levels and global BILAG score in eight patients with SLE over time. Time points on
the x axis are successive follow-up visits. IgG anti-apoA-1 parallels global disease activity in many (A) to (F) but not all (G), (H) patients. anti-apoA-
1, antibodies to apolipoprotein A-1; AU, absorbance units; BILAG, British Isles Lupus Assessment Group; IgG, immunoglobulin G.
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ture [1,4]. Longer-term studies may well be needed in SLE
than in RA to identify predictive effects of factors such as
autoantibodies on CVD risk. Notably, in a large inception
cohort study, 1,249 patients with SLE were followed for a
median of 8 years and only older age and male gender
were identified as CVD risk factors in multivariable ana-
lysis [30].
Our study had a number of limitations. We did not
study different isotypes of IgG anti-apoA-1 antibodies.
In future, it may be worthwhile to investigate whether
specific isotypes are more strongly associated with over-
all or organ-specific disease activity. We defined CVD by
review of the notes and did not have detailed informa-
tion on CVD events (such as troponin rise and degree of
arterial stenosis). Other studies, such as those of Vuilleu-
mier and colleagues defined CVD using harder end-
points [9,11]. The number of patients in the longitudinal
group was relatively small at 49. The surprising finding
that elevated IgG anti-apoA-1 levels were associated
with negativity for anti-Sm and anti-La thus needs to be
confirmed in a larger cohort. If this is confirmed, it may
be useful to investigate whether associations of IgG
anti-apoA-1 and different forms of disease activity are
different in anti-Sm-positive or anti-La-positive versus
anti-Sm-negative or anti-La-negative patients.
Previously we showed that IgG anti-apoA-1 levels were
higher in patients with persistently active disease than qui-
escent disease and rose at times of disease flare [2]. How-
ever, we did not study serial samples taken over long
periods and were unable to carry out multivariable ana-
lysis. By studying samples taken from 49 patients longi-
tudinally, we have confirmed the association of IgG
anti-apoA-1 level with disease activity, particularly
haematological activity. The association with haemato-
logical activity, however, may arise partly from the fact
t h a tt h e r ew e r em o r ep a t i e n t sw i t hB I L A GAo rB
scores in the haematology system than in any other sys-
tem. In previous papers we have also demonstrated as-
sociations between serological markers and activity in
particular systems: anti-nucleosome antibodies and
renal lupus [31], interleukin-6 and haematological lupus
[32], and nitrated nucleosomes and vasculitis [33].
Hydroxychloroquine was associated with lower IgG
anti-apoA-1, and high-dose corticosteroids with higher
Figure 3 Kaplan–Meier survival curve comparing percentage
CVD-free survival in patients who were anti-apoA-1-positive
(n=135) and anti-apoA-1-negative (n=364) in their early disease
sample. Time (x axis) measured in years. The number of subjects at risk
at each time point was as follows: 499 at time 0, 275 at 10 years, 94 at
20 years and 27 at 30 years. anti-apoA-1, antibodies to apolipoprotein
A-1; CVD, cardiovascular disease.
Table 3 Mean damage scores over 20 years stratified by quartile of serum IgG anti-apoA-1 level in the early disease
sample
Lowest quartile Second quartile Third quartile Highest quartile
Damage score at 1 year (n=236) 0.14 0.13 0.10 0.08
Damage score at 5 years (n=236) 0.63 0.43 0.45 0.42
Damage score at 10 years (n= 209) 1.06 0.60 0.96 0.65
Damage score at 15 years (n= 131) 1.23 0.81 1.33 0.97
Damage score at 20 years (n= 69) 1.33 1.06 1.88 1.00
anti-apoA-1, antibodies to apolipoprotein A-1; IgG, immunoglobulin G.
Figure 4 Kaplan–Meier survival curve comparing percentage
survival in patients who were anti-apoA-1-positive (n=135) and
anti-apoA-1-negative (n =364) in their early disease sample. Time
(x axis) measured in years. The number of subjects at risk at each time
point was as follows: 499 at time 0, 290 at 10 years, 103 at 20 years and
31 at 30 years. anti-apoA-1, antibodies to apolipoprotein A-1.
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varied in parallel with disease activity over time. These
results, however, do not prove a causal relationship be-
tween presence of IgG anti-apoA-1 antibodies and de-
velopment of inflammation or disease activity in SLE.
The possibility of a causal relationship would be an in-
teresting question for future work.
Conclusion
In summary, this comprehensive analysis shows that IgG
anti-apoA-1 antibodies are found commonly in patients
with SLE and develop early in the disease course. Levels
are associated with high disease activity and treatment
with corticosteroids, but we have shown no convincing
link with CVD. It remains possible that such a link will be
shown in longer-term studies or by studying more sensi-
tive measures of atherosclerosis such as plaque echogeni-
city, thickness, area or volume using vascular ultrasound
scanning [34,35].
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